3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Mesothelioma, Malignant
2
Melanoma
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
PD-L1 Positive Mutation Tumor
1
Metastatic Solid Tumors
1
Mesothelioma
1
Malignant Solid Tumour
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
Injections
27
Carboplatin
18
Docetaxel
14
pembrolizumab
13
Paclitaxel
12
Bevacizumab
10
durvalumab
8
Nivolumab
8
Cisplatin
8
Fluorouracil
7
Pemetrexed
6
Oxaliplatin
6
Leucovorin
6
trifluridine tipiracil drug combination
5
toripalimab
5
tislelizumab
5
linifanib
5
Capecitabine
5
zimberelimab
4
talazoparib
4
olaparib
4
fludarabine
4
Panobinostat
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Everolimus
4
tremelimumab
3
sotorasib
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
avelumab
×
Other solid neoplasm
×
Clear all
NCT02994953
2024-09-20
COMBO
EMD Serono
Phase 1
Terminated
52 enrolled
34 charts